Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-04-15
2008-04-15
Spivack, Phyllis G. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
11047142
ABSTRACT:
A therapeutic method and pharmaceutical compositions for treatment of irritable bowel syndrome including non-constipated irritable bowel syndrome such as diarrhea-predominant irritable bowel syndrome and alternating constipation/diarrhea irritable bowel syndrome in male and female patients, which may comprise administering a patient with from 0.001 to 0.05 mg of ramosetron hydrochloride as a daily dose or an equivalent molar amount of ramosetron or its pharmaceutically acceptable other salt.
REFERENCES:
patent: 4067974 (1978-01-01), Sasmor
patent: 5223508 (1993-06-01), Izawa et al.
patent: 5344927 (1994-09-01), Ohta et al.
patent: 2002/0040033 (2002-04-01), Cautreels et al.
patent: 2002/0150624 (2002-10-01), Watanabe et al.
patent: 2003/0143548 (2003-07-01), Camilleri et al.
patent: 2005/0026981 (2005-02-01), Sugihara et al.
patent: 0 274 845 (1988-07-01), None
patent: 1 205 190 (2002-05-01), None
patent: 5-6226 (1999-03-01), None
patent: WO 99/17755 (1999-04-01), None
The Merck Manusal, 17thedition (1999), p. 312.
M. Ohta et al., Chem. Pharm. Bull., 44(5):991-999 (1996).
M. Ohta et al., Chem. Pharm. Bull., 44(5):1000-1008 (1996).
M. Ohta et al., Chem. Pharm. Bull., 44(9):1707-1716 (1996).
M. Ohta et al., Chem. Pharm. Bull., 44(9):1717-1722 (1996).
K. Miyata et al., Journal of Pharmacology and Experimental Therapeutics, 261(1):297-303 (1992).
K. Miyata et al., American Physiological Society, pp. G827-G831 (1998).
T. Hirata et al., Pharmacology Laboratories, Institute for Drug Discovery Research, Yamanouchi Pharmaceutical Co., Ltd., pp. 1-6 (2003) (including English language translation).
Japanese Pharmaceutical Excipients Dictionary, First Edition, complied by Japan Pharmaceutical Excipients Council and published by Yakuji Nippo, Ltd. (Jan. 14, 1994), p. 2, “Ascorbic Acid” section; p. 3, “L-Aspartic Acid” section; p. 18 “Erythorbic Acid” section; pp. 38 to 39, “Citric Acid” section; p. 65, “Tartaric Acid” section; p. 113, “Fumaric Acid” section; p. 117, “Propyl Gallate” section.
K. Masaki et al., Kagakurycho no Ryoiki, 14(11):2004-2008 (1998).
T. Kuwabara et al., J. Gastroenterol., 29:721-726 (1994).
N. Kishibayashi et al., J. Med. Chem., 36:3286-3292 (1993).
Japan Pharmaceutical Reference, The Fifth Edition (1999), Nasea Injection 0.3 mg (p. 1278-1280) and Nasea OD Tablets 0.1 mg (p. 1281-1283).
Ramosetron hydrochloride,Drugs of the Future, vol. 21, No. 1, 1996, 116-116.
A. Ozaki et al. Effect of the 5-hydroxytryptamine3(5-ht3)-receptor antagonist KB-R6933 on experimental diarrhea models,Jpn. J. Pharmacol., vol. 80, 1999, 93-96, XP009047033.
H. Ito, et al. Investigation of the effects of YM-31636, a novel 5-ht3receptor agonist, on defecation in normal and constipated ferrets, European Journal of Pharmacology, vol. 424, 2001, 151-157.
C. Steadman et al. Selective 5-Hydroxytryptamine Type 3 Receptor Antagonism with Ondansetron as Treatment for Diarrhea-Predominant Irritable Bowel Syndrome: A Pilot Study, Mayo Clinic Proceedings, Mayo Medical Ventures, Rochester, MN, US, vol. 67, No. 8, Aug. 1992, 732-738, XP002098638.
G. Stacher et al. Effects of the 5-HT3Antagonist Cilansetron vs Placebo on Phasic Sigmoid Colonic Motility in Healthy Man: a Double-Blind Crossover Trial, British Journal of Clinical Pharmacology, Blackwell Scientific Publ, GB, vol. 49, No. 5, 2000, 429-436.
T. Hirata et al., Usefulness of 5-HT3 receptor antagonists in irritable bowel syndrome—pharmacological profile of ramosetron hydrochloride,Saibo, 2003, vol. 35, No. 10, p. 398-401.
Kikuta et al., Japanese Journal of Pediatrics, 52:425-432 (1999).
Noda et al., Japanese Journal of Clinical and Experimental Medicine, 71(10):2753-2764 (1994).
Nakajima et al., The Japanese Journal of Clinical and Experimental Medicine, 71(9):2461-2468 (1994).
Sekino et al., Japanese Pharmacology and Therapeutics, 22(9):3877-3888 (1994).
Noda et al., The Japanese Journal of Clinical and Experimental Medicine, 71(10):2765-2776 (1994).
Noda et al., Journal of New Remedies & Clinics, 43(11):2241-2255 (1994).
Taketani et al., The World of Obstetrics and Gynecology, 46(12):965-973 (1994).
Taketani et al., Obstetrics & Gynecology, 61(12):1759-1770 (1994).
Kawabata et al., Nishinihon Journal of Urology, 56:1445-1456 (1994).
Mori et al., The Journal of Adult Diseases, 24(12):2257-2265 (1994).
Sato et al., Japan Journal of Cancer Clinics, 50(4):305-313 (2004).
Noda et al., Journal of New Remedies & Clinics, 45(7):1309-1321 (1996).
Noda et al., Journal of New Remedies & Clinics, 45(3):482-490 (1996).
Taketani et al., Obstetrics & Gynecology, 63(9):1297-1308 (1996).
Taketani et al., The World of Obstetrics and Gynecology, 48(8):749-760 (1996).
Noda et al., Journal of New Remedies & Clinics, 45(8):1445-1462 (1996).
Atsuta Yutaka
Nishida Akito
Niwa Akira
Astellas Pharma Inc.
Corless Peter F.
Edwards Angell Palmer & & Dodge LLP
Spivack Phyllis G.
LandOfFree
Treating agent for irritable bowel syndrome does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treating agent for irritable bowel syndrome, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treating agent for irritable bowel syndrome will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3922046